Table 1.
Evaluation of the appropriateness and comprehensiveness of using ChatGPT for perioperative patient education in thoracic surgery in different language contexts (English and Chinese).
| Question | Appropriateness, Ya | Comprehensiveness, Y | |||||
|
|
English (n=24), n (%) | Chinese (n=35), n (%) | P value | English (n=24), n (%) | Chinese (n=35), n (%) | P value | |
| Q1: What is lung cancer? | 24 (100) | 32 (91) | .26 | 15 (62) | 25 (71) | .47 | |
| Q2: What are the causes of lung cancer? | 23 (96) | 32 (91) | .64 | 22 (92) | 30 (86) | .69 | |
| Q3: How can I prevent lung cancer? | 21 (88) | 32 (91) | .68 | 21 (88) | 28 (80) | .51 | |
| Q4: What are the symptoms of lung cancer? | 23 (96) | 33 (94) | .99 | 21 (88) | 31 (89) | .99 | |
| Q5: Why do some lung cancer patients develop hoarse voice as a symptom? | 15 (62) | 22 (63) | .99 | 11 (46) | 19 (54) | .60 | |
| Q6: What diagnostic tests should be performed to diagnose lung cancer? | 24 (100) | 31 (89) | .14 | 19 (79) | 33 (94) | .11 | |
| Q7: How can I determine if a lung nodule is benign or malignant? | 23 (96) | 33 (94) | .99 | 22 (92) | 32 (91) | .99 | |
| Q8: What precautions should be taken prior to lung cancer surgery? | 22 (92) | 31 (89) | .99 | 19 (79) | 31 (89) | .46 | |
| Q9: What are the complications that may arise from lung cancer surgery? | 24 (100) | 31 (89) | .14 | 22 (92) | 28 (80) | .29 | |
| Q10: What is Mobocertinib? | 24 (100) | 32 (91) | .26 | 19 (79) | 32 (91) | .25 | |
| Q11: What is Amivantamab-vmjw? | 24 (100) | 34 (97) | .99 | 23 (96) | 33 (94) | .99 | |
| Q12: What is Adagrasib? | 23 (96) | 33 (94) | .99 | 21 (88) | 32 (91) | .68 | |
| Q13: Do EGFRb-positive lung cancer patients who have received adjuvant chemotherapy also require adjuvant targeted therapy? | 24 (100) | 34 (97) | .99 | 21 (88) | 32 (91) | .68 | |
| Q14: Is local treatment necessary for oligometastatic lung cancer? | 24 (100) | 33 (94) | .51 | 19 (79) | 33 (94) | .11 | |
| Q15: Can Osimertinib be considered for EGFR-positive lung cancer patients with brain metastasis but without T790m mutation? | 23 (96) | 32 (91) | .64 | 22 (92) | 32 (91) | .99 | |
| Q16: Why is lung cancer gene mutation testing necessary and who should undergo this testing? | 23 (96) | 31 (89) | .64 | 21 (88) | 31 (89) | .99 | |
| Q17: What should I do if my CEAc level is found to be abnormal after 1 year of lung cancer surgery? | 24 (100) | 32 (91) | .26 | 24 (100) | 33 (94) | .51 | |
| Q18: What is the cause of subcutaneous emphysema after lung cancer surgery and how can it be treated? | 24 (100) | 34 (97) | .99 | 21 (88) | 31 (89) | .99 | |
| Q19: How can lung infections be prevented after lung cancer surgery? | 21 (88) | 30 (86) | .99 | 16 (67) | 30 (86) | .11 | |
| Q20: How can the development of deep vein thrombosis be prevented after surgery? | 23 (96) | 29 (83) | .22 | 18 (75) | 28 (80) | .75 | |
| Q21: What is the cause of an unpleasant odor from the surgical wound and how can it be treated? | 24 (100) | 34 (97) | .99 | 22 (92) | 33 (94) | .56 | |
| Q22: What is a closed thoracic drainage tube and what precautions should be taken? | 23 (96) | 31 (89) | .64 | 19 (79) | 30 (86) | .73 | |
| Q23: How often should lung cancer patients undergo follow-up exams and what tests should be performed? | 24 (100) | 34 (97) | .99 | 16 (67) | 28 (80) | .36 | |
| Q24: What is esophageal cancer and its definition? | 24 (100) | 34 (97) | .99 | 22 (92) | 33 (94) | .99 | |
| Q25: What are the causes of esophageal cancer? | 23 (96) | 31 (89) | .64 | 22 (92) | 32 (91) | .99 | |
| Q26: How can one prevent the onset of esophageal cancer? | 24 (100) | 34 (97) | .99 | 24 (100) | 33 (94) | .51 | |
| Q27: What are the symptoms of esophageal cancer? | 24 (100) | 29 (83) | .07 | 21 (88) | 29 (83) | .73 | |
| Q28: What diagnostic tests should be performed to diagnose esophageal cancer? | 23 (96) | 32 (91) | .64 | 21 (88) | 31 (89) | .99 | |
| Q29: What are the potential complications of esophageal cancer surgery? | 22 (92) | 32 (91) | .99 | 13 (54) | 21 (60) | .79 | |
| Q30: How can a patient determine if targeted therapy is necessary for their esophageal cancer? | 24 (100) | 31 (89) | .14 | 18 (75) | 31 (89) | .29 | |
| Q31: I experience hoarseness after surgery for esophageal cancer, what should I do? | 12 (50) | 20 (57) | .59 | 11 (46) | 19 (54) | .60 | |
| Q32: If pleural fluid turns milky white in the chest tube following esophageal cancer surgery, what could be the cause and what steps should be taken? | 9 (38) | 15 (43) | .68 | 4 (17) | 9 (26) | .53 | |
| Q33: What is anastomotic leak after esophageal cancer and how can it be managed? | 22 (92) | 32 (91) | .99 | 18 (75) | 29 (83) | .46 | |
| Q34: What is Nivolumab? | 23 (96) | 31 (89) | .64 | 18 (75) | 30 (86) | .33 | |
| Q35: Why is a jejunostomy tube used after esophageal cancer surgery and what precautions should be taken? | 24 (100) | 31 (89) | .14 | 18 (75) | 30 (86) | .33 | |
| Q36: How can lung infection be prevented after esophageal cancer surgery | 22 (92) | 32 (91) | .99 | 15 (62) | 30 (86) | .06 | |
| Q37: How often should individuals undergo follow-up after esophageal cancer surgery and what tests should be performed? | 24 (100) | 31 (89) | .14 | 24 (100) | 31 (89) | .14 | |
aY: yes.
bEGFR: epidermal growth factor receptor.
cCEA: carcinoembryonic antigen.